This study aims to observe the safety and effectiveness of intravenous thrombolysis for acute ischemic stroke in real-world clinical practice.
IVTIS is a prospective, real-world registry lasting for 22 years. A total of 3000 patients with intravenous thrombolysis will be enrolled。
Study Type
OBSERVATIONAL
Enrollment
3,000
Intravenous thrombolysis using thrombolytic drugs such as ateplase and teneplase.
Affiliated Hospital of Southwest Medical University
Luzhou, China
RECRUITINGmodified Rankin Scale (mRS) score
Ordinal distribution of mRS at 90±7 days; modified Rankin scale (range, 0 to 6, with a score of 0 indicating no disability, 1 no clinically significant disability, 2 slight disability, 3 moderate disability but remaining able to walk unassisted, 4 moderately severe disability, 5 severe disability, and 6 death)
Time frame: 90±7 days
Excellent functional outcome
Proportion of subjects with mRS 0-1 at 90±7 days.
Time frame: 90±7 days
Good functional outcome
Proportion of subjects with mRS 0-2 at 90±7 days.
Time frame: 90±7 days
mRS 0-3
Proportion of subjects with mRS 0-3 at 90±7 days.
Time frame: 90±7 days
Change of National Institutes of Health Stroke Scale (NIHSS)
Change of National Institutes of Health Stroke Scale (NIHSS, a scale between 0 and 42 on which higher scores indicate more severe neurologic deficits) from baseline to 24 hours.
Time frame: 24 hours
Change of National Institutes of Health Stroke Scale (NIHSS)
Change of National Institutes of Health Stroke Scale (NIHSS, a scale between 0 and 42 on which higher scores indicate more severe neurologic deficits) from baseline to 7 days.
Time frame: 7 days
Symptom-to-thrombolysis time
Time from onset of symptoms to thrombolytic therapy.
Time frame: 24 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Door-to-Needle Time
Time from the arrival of stroke patient in emergency to initiation of thrombolysis therapy.
Time frame: 24 hours
Incidence of clinically significant intracranial hemorrhage
Incidence of sICH (Heidelberg criteria) measured at 36 hours
Time frame: 36 hours
Incidence of any intracranial hemorrhage
Incidence of any intracranial hemorrhage (Heidelberg criteria) measured at 36 hours
Time frame: 36 hours
All-cause mortality
All-cause mortality at 90±7 days
Time frame: 90±7 days
Complications related to intravenous thrombolysis
Complications related to intravenous thrombolysis during hospitalization
Time frame: up to 7 days